From quality assured
to rest assured

As the nation’s largest network of outsourcing admixture pharmacies and a leading provider of 503A compounded sterile preparations (CSPs), Central Admixture Pharmacy Services (CAPS®) understands the importance of reliable access to high-quality medications. Our team of experts is passionate about providing just that, while also simplifying your operations by reducing the risks, costs and resource demands of in-house compounding. We offer 21 503A regional pharmacies registered to dispense your customized, patient-specific compounding needs. Above all, your patients are at the center of everything we do. And as your trusted partner, we’re committed to providing the products that help them live healthier, more secure lives.

An important message from CAPS and B. Braun Medical Inc.

CAPS has made the decision to exit the 503B sterile compounding business as part of a strategic refocus on its core operations and long-term sustainability.

The decision represents a shift to focus on our CAPS 503A compounding business where we will continue to support and invest in our nationwide network of pharmacies and capabilities. CAPS 503A compounding business remains a critical part of the B. Braun portfolio, delivering high-quality, reliable, patient-specific solutions to hospital and outpatient providers through 21 locations across the United States.

To support continuity of care, CAPS will continue to supply certain 503B products for approximately ninety (90) days to allow customers sufficient time to identify alternative suppliers and complete transition planning. 

CAPS stands by the safety and quality of all its products currently in the market, as well as those that will be distributed during the wind‑down period. 

We appreciate our customers’ long-standing support. Our priority during this time is to minimize disruption for them and the patients they serve.